IceCure signs exclusive ProSense distribution deal with Scovas in Netherlands

ICCM•2026-08-24

Clinical and commercialization context

IceCure said the agreement is intended to support commercialization expansion, clinical education and physician access in a market linked to the Netherlands-based THERMAC trial.

THERMAC investigators advanced cryoablation into Phase III. Earlier data cited 94% success, 0% complication and 100% tolerance without general anesthesia.

Exclusive distribution deal for the Netherlands

IceCure signed an exclusive distribution agreement with Scovas Medical for its ProSense cryoablation systems in the Netherlands.

The deal covers breast cancer treatment and interventional oncology. The initial term also includes plans to negotiate a longer-term agreement.

IceCure signs exclusive ProSense distribution deal with Scovas in Netherlands

Clinical and commercialization context

Exclusive distribution deal for the Netherlands

Related News

Moog partners with Voltaic Marine on autonomous unmanned surface vessel development

U.S. Treasury to broaden scope of secondary sanctions on Iran, source says

Agencia Comercial Spirits CFO Liu Shihao steps down as executive director

IceCure signs exclusive ProSense distribution deal with Scovas Medical in Netherlands

Workday, Inc. <WDAY.O>: Oppenheimer raises target price to $220 from $165